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ABSTRACT
Introduction In the new era of effective systemic 
therapies for advanced melanoma, early detection of lower 
volume recurrent disease using surveillance imaging can 
improve survival. However, intensive imaging follow- up 
strategies are likely to increase costs to health systems 
and may pose risks to patients. The objective of this 
study is to estimate from the Australian health system 
perspective the cost- effectiveness of four follow- up 
strategies in resected stage III melanoma over a 5- year 
period following surgical treatment with curative intent.
Methods and analysis A decision- analytic model will 
be built to estimate the costs and benefits of (1) 12 
monthly, (2) 6 monthly, (3) 3–4 monthly positron emission 
tomography/CT imaging for 5 years, compared with (4) 
no imaging follow- up. The model will be populated with 
probabilities of disease recurrence, test performance 
measures using data from >1000 consecutive resected 
stage III melanoma patients from Melanoma Institute 
Australia diagnosed between 2000 and 2017. Healthcare 
resource use, including surveillance imaging, doctor’s 
visits, subsequent tests and procedures to investigate 
suspicious findings, will be quantified from detailed 
patient records and valued using Australian reference 
pricing. Economic outcomes include cost per new distant 
melanoma recurrence detected and cost per diagnostic 
error avoided, for no imaging compared with the other 
strategies.
Deterministic sensitivity analyses will examine the 
robustness of model results.
Ethics and dissemination This study was approved 
by the Sydney Local Health District, Sydney Local 
Health District Ethics Review Committee (RPAH Zone), 
AU/1/830638 and the Australian Institute of Health and 
Welfare (EO2019-1-454). The results of this study will be 
published in peer- reviewed medical and health economics 




In Australia, melanoma is the third most 
common cancer in both men and women, 
accounting for 10% of all new cases (13 280: 
7850 women and 5440 men) and 3.8% of 
cancer deaths (1775: 545 women and 1230 
men) in 2016.1 Its incidence is continuing to 
rise slowly in both sexes, and while mortality 
and 5- year survival (95%) after melanoma 
diagnosis are stable, the disease remains a 
leading cause of cancer death in young adults 
aged under 40.
Stage III melanoma is defined as the pres-
ence of metastatic disease in regional lymph 
nodes and/or the presence of intransit/satel-
lite/microsatellite metastasis.2 3 The dissem-
ination of melanoma to regional nodes and 
visceral organs, such as the lung, liver or 
brain, implies a poor prognosis. The risk of 
recurrence is highest in the first 3 years after 
diagnosis,4 but patients have a life long risk 
of relapse. Appropriate surveillance can iden-
tify disease recurrence and enable early indi-
vidualised treatment.5 However, there is no 
randomised trial evidence that early recog-
nition and treatment of systemic recurrence 
improve survival outcomes.3
Follow-up strategies
In melanoma clinics, after treatment for 
initial stage III disease, patients are routinely 
followed up for at least 5 years3 6 with clinical 
Strengths and limitations of this study
 ► The analysis will be based on test accuracy and 
prevalence data from a cohort study of over 1000 
patients with stage III melanoma.
 ► The model structure accounts for clinical and policy- 
relevant outcomes including test accuracy.
 ► The comparison of the three imaging schedules was 
not based on data from randomised trials and some 
selection bias might be introduced.
 ► Treatment cost data will be obtained from the pub-
lished literature.
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examination and various imaging tests. CT, positron emis-
sion tomography (PET) or PET/CT specifically assess for 
evidence of systemic recurrence. CT is a medical imaging 
modality that uses ionising radiation and computer 
processing to generate detailed anatomical scans of the 
body. Whole- body CT including chest, abdomen and 
pelvis±the brain can detect cancer metastases as small as 
2–4 mm.7 Reported CT detection rates range from as high 
as 72% of distant metastases in asymptomatic patients in 
one study using clinical follow- up as reference standard8 
to 15%–28% in another study with whole- body MRI as 
reference standard.9 Drawbacks to CT are its limited soft 
tissue contrast, cost and radiation exposure, with an effec-
tive dose of up to 20 mSv per test.10
PET registers metabolic and biochemical activity, 
however, the images produced lack fine anatomical detail. 
Images from both modalities (CT and PET) can be taken 
sequentially, combined and superimposed to create one 
functional and detailed imaging sequence. This PET/
CT combines functional imaging from the PET scan with 
specific anatomical images from the CT; if any areas of 
tumour activity are detected, the superimposed CT scan 
pinpoints the location. High accuracy of PET/CT has 
been reported by recent studies assessing the ability of 
PET/CT to detect distant metastases. Danielsen et al5 
pooled the findings for seven studies that investigated 
PET/CT in follow- up of cutaneous malignant melanoma 
and found a pooled sensitivity and negative predictive 
value of 96% and 95%. Another systematic review by 
Rodriguez et al11 reported an overall sensitivity of 89.4% 
and a specificity of 88.8% in detecting metastases in stage 
III melanoma patients.
Surveillance imaging during follow- up for resected 
stage III melanoma patients at risk of systemic recurrence 
remains controversial.12 13 Potential benefits include early 
detection of distant disease that induces a change in 
management (eg, treatment with surgery, systemic ther-
apies, radiotherapy or enrolment in clinical trials of new 
treatments), which may lead to better survival outcomes 
than if patients were diagnosed and treated once symp-
tomatic (with higher disease burden).14 Patients also 
report feeling reassured by regular imaging.15 The disad-
vantages include exposure to radiation that can increase 
the risk of cancer in the future16 17; incidental findings 
that are later found to be harmless, causing unnecessary 
investigations and anxiety18; added downstream tests 
including both image- guided biopsies and short- term 
additional cross- sectional imaging follow- up as a result of 
equivocal findings, to prove or rule out melanoma metas-
tasis19 and possible complications of these tests, such as 
bleeding from biopsy of a suspected visceral metastasis. 
However, not all incidental findings will later be found 
to be harmless. Some will be treated and the patient will 
get better, and it is only by looking at population- level 
mortality data that we are able to ascertain that some of 
these cancers must have harmless.
Current guidelines
International guidelines for follow- up after treatment 
of stage III melanoma vary considerably with respect to 
surveillance imaging, illustrating the paucity of high- level 
evidence. The German guidelines recommend CT or 
PET/CT every 6 months for the first 3 years for resected 
stage III patients20; The US guidelines recommend 
imaging every 4–12 months for the first 5 years,21 while 
the UK National Institute for Health and Care Excellence 
guidelines recommend surveillance imaging only if there 
is a clinical trial investigating the value of regular imaging 
or a local policy with specific funding for 6 monthly 
imaging for 3 years.22 The Australian Melanoma Guide-
lines (2018) state CT of the chest, abdomen and pelvis 
or PET may be performed prior to definitive therapy 
where the detection of metastatic disease would influence 
management.3 Ultrasound assessment can detect locore-
gional recurrence, but it is not applicable for detection 
of systemic recurrence, and not recommended by Austra-
lian guidelines. Currently there is no high- level evidence 
that early detection and management of recurrence from 
surveillance imaging improves patient outcomes.
Cost-effectiveness of surveillance imaging
Few research studies have investigated the cost- 
effectiveness of a surveillance imaging strategy in resected 
stage III melanoma patients.23–25 Mostly the published 
studies have reported costs and benefits of one- off (base-
line) imaging prior to surgery or imaging to assess treat-
ment response in the management of distant (stage IV) 
disease as well as exploring whether annual imaging to 
detect systemic recurrence for resected stage III mela-
noma patients is more effective than no annual imaging, 
there is a need to investigate and establish its relative 
cost- effectiveness for the identification of melanoma 
recurrence.
The follow- up strategies in current practice were devel-
oped before potentially effective systemic therapies that 
were available to treat advanced melanoma and also 
before patients with stage III melanoma received adju-
vant therapy (where different adjuvant treatments have 
different recurrence risks, particularly in the first 1–2 
years). These new therapies have significant benefits for 
patients, and in the metastatic setting, the potential to be 
most efficacious in patients with lower disease burden.26 
Therefore, it might be beneficial to identify recurrence 
earlier for patients who might benefit more from earlier 
systemic treatment. This study aims to investigate the 
‘opportunity cost’ of surveillance imaging by exploring 
the cost- effectiveness of four surveillance strategies 
(see table 1) for the diagnosis and treatment of distant 
melanoma recurrence by modelling the relative costs 
and benefits accrued from (a) no- scheduled imaging 
follow- up compared with: (b) 12 monthly imaging: one 
PET/CT scan per year for 5 years, (c) 6monthly imaging: 
two PET/CT scans per year for 5 years, (d) 3–4 monthly 
PET/CT imaging for 5 years: (involves routine imaging 
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every 3 months during the first 3 years, every 6 months in 
years 4–5).
METHODS AND ANALYSIS
Patients and data source
This prospective cohort study identified consecutive 
resected stage III melanoma patients with American 
Joint Cancer Committee eighth edition stage III disease,2 
treated at Melanoma Institute Australia (MIA) between 
the years 2000 and 2017 and entered into the research 
database at MIA. We included stage IIIA–D melanoma 
patients who had received surgical treatment with cura-
tive intent had no evidence of further disease postopera-
tively and were followed- up clinically at MIA to assess for 
recurrence. Many patients underwent repeated surveil-
lance imaging as a part of their scheduled follow- up. We 
also identified a cohort of patients with standard clinical 




To assess the cost- effectiveness of a no- imaging follow- up 
strategy compared with 12 monthly, 6 monthly and 3–4 
monthly imaging, a decision tree will be built in TreeAge 
software (TreeAge Software, Williamstown, Massachu-
setts, USA). The model will start with patients receiving 
one of four follow- up strategies: (1) routine 12 monthly 
imaging, (2) routine 6 monthly imaging, (3) 3–4 
monthly imaging or (4) follow- up without imaging (see 
figure 1). Each branch of the decision tree will repre-
sent a follow- up strategy under assessment and will be 
parameterised with data on diagnostic accuracy, costs and 
recurrence obtained from our prospective cohort and 
from published literature over a time horizon of 5 years. 
Two economic outcomes will be assessed: cost per case of 
distant recurrence appropriately identified and cost per 
diagnosis error avoided.
Model assumption
The model assumptions include:
a. Surveillance imaging is primarily used to identify sys-
temic recurrence. Locoregional melanoma recurrence 
is often identified by physical examination in contrast 
to distant disease, which is difficult to detect by physi-
cal examinations. Thus PET/CT imaging surveillance 
is predominantly undertaken to identify distant meta-
static disease.27
b. Systemic recurrence occurs only once for patients 
who progress. Therefore, the model will simulate 
the costs and benefits up to the first (initial) systemic 
recurrence.
c. In the absence of histopathology, disease status after 6 
months of clinical follow- up will be used as a reference 
standard for PET/CT imaging.
d. Based on Australian guidelines,3 patients with positive 
imaging test results will undergo confirmatory investi-
gations: fine- needle aspiration biopsy, core biopsy, se-
rum lactate dehydrogenase, whole body PET/CT, MRI 
of the brain and gene mutation testing.
e. The costs for unresectable stage III or stage IV 
melanoma treatments included standard imaging, 
medical appointments, genetic testing and pharma-
cotherapies where relevant as well as costs for grades 
3 and 4 adverse events for pharmacotherapies (eg, 
colitis).
f. Costs of palliative and end of life care will be excluded. 
As the main outcomes, the effectiveness end point ap-
plied was the detection and treatment of distant recur-
rence, the costs of end of life care were not included in 
the economic analysis.
IMAGING SURVEILLANCE STRATEGIES
We will evaluate the ability of the four surveillance strat-
egies to detect systemic recurrence for each patient in 
the respective cohort. Table 1 describes the different 
follow- up strategies.
Table 1 Follow- up strategy description
Follow- up strategy Description
Intervention No imaging follow- up No further routine imaging during follow- up.
Clinical visit every 4 months for the first 3 years, every 6 months in years 
4–5. Patients receive imaging if either the patient or doctor identifies signs/
symptoms suggesting recurrence
Comparators Intensive surveillance 
imaging
Patients given routine imaging every 3–4 months during the first 3 years, 
every 6 months in years 4–5. Clinical visit with a melanoma specialist at the 
time of each scan
Routine 6- monthly 
imaging
Two PET/CT scans per year for 5 years.
Clinical visit with a melanoma specialist at the time of each scan +every 3 
months in between
Routine 12- monthly 
imaging
One PET/CT scan per year for 5 years.
Clinical visit with a melanoma specialist at the time of the scan
PET, positron emission tomography.
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DATA REQUIRED FOR THE MODEL
Prevalence data
We will populate the decision model with the prevalence 
of distant melanoma recurrence from our MIA cohort. 
For each follow- up strategy, the prevalence of systemic 
recurrence will be calculated.
Test accuracy data
PET/CT sensitivity and specificity over a 5- year period 
will be derived from a cohort study we conducted among 
332 resected stage III melanoma patients (median 
follow- up 61 months). This analysis has provided data 
regarding the diagnostic accuracy of PET/CT at each 
3, 6 and 12 monthly follow- up time points. (table 2). 
The result of PET/CT imaging will be classified as true 
positive (TP), if metastatic disease was detected by the 
surveillance imaging. PET/CT findings will be defined 
as true negative (TN), if the scan was negative and no 
distant disease was detected during further follow- up. 
PET/CT results will be defined as false negative (FN), if 
the scan was negative, but recurrent disease was detected 
during 6- month follow- up by other tests or physical 
examination in clinical follow- up. PET/CT findings will 
be defined as false positive (FP), if the scan indicated 
melanoma or suspicion for melanoma, but the refer-
ence standard confirmed there was no melanoma.
Healthcare resource use and costs
Healthcare resources will include all imaging, confir-
matory tests and blood tests, medical appointments 
and subsequent treatment, following the initial surgical 
management of stage III melanoma (table 3). Health-
care use incurred to diagnose stage III disease or to treat 
it surgically will be excluded. To account for the cost of 
Figure 1 Decision model structure. PET, positron emission tomography.
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incidental findings, our model will include the costs of 
further investigations (eg, extra scans, diagnostic biop-
sies) following an FP result resource use will be identified 
from each patient’s detailed medical records at MIA.
The costs of resource utilisation will be estimated from 
the perspective of the Australian health system. Resource 
use will be valued using unit costs from the Medicare 
Benefits Schedule for diagnostic tests and outpatient 
care and Australian Refined Diagnosis Related Groups 
for hospital admissions.28 Treatment costs following 
a melanoma recurrence or stage IV diagnosis will be 
derived from published Australian study.29 All costs will be 
adjusted to 2020 prices and 5% discounting per annum 
will be applied.30
Outcomes
We will report two different effectiveness/outcome 
measures from an Australian health system perspective: 
the cost per new distant melanoma recurrence detected 
and treated, and the cost per diagnostic error avoided.
Outcome for recurrent melanoma appropriately diagnosed
For distant recurrent melanoma appropriately diagnosed 
and treated, we will use the difference between the TP 
and FN value from our cohort study. We will give a value 
of 1 to TP and 0 to FN. For convenience, we will give the 
value 1 for FP and TN, therefore, we will only give the 
value of 0 for an erroneous identification.
Outcome for diagnostic error avoided
For the outcome of diagnostic error avoided, no effec-
tiveness data are required. The TP and TN cases will be 
given the value of 1. TPs and FNs will be given the value 
of 0.
Table 2 Test performance of PET/CT surveillance imaging
Investigation Sensitivity (95% CI) Specificity (95% CI) Reference
3–4 monthly imaging 79% (70% to 86%) 88.6% (86.4 to 90.5) 32
12- monthly imaging 79% (70% to 86%) 88.6% (86.4 to 90.5) 32
6- monthly imaging 79% (70% to 86%) 88.6% (86.4 to 90.5) 32
No imaging follow- up 71.4% (55.4–84.3) 99.6% (99.2 to 99.8) 33
PET, positron emission tomography.
Table 3 Cost inputs for the model, 2019 Australian dollars
Test Site




Whole body PET/CT Whole body 1397 MBS #57007, MBS 
#61 553
Ultrasound Regional lymph node 93 MBS #55 812
MRI Brain and head 343 MBS #63 001
X- ray Chest and abdomen 81 MBS # 58903, MBS # 
58 503
FNAB Solid tissue or tissues 
from two or more sites
188 MBS # 73 066
Bone scan Whole body 408 MBS # 61 421
Clinical follow- up (Specialist) 66 MBS #116
Mutation analysis Stage III/IV tumour 
tissue
196 MBS # 73 336
Core biopsy Lymph node, muscle 
or other deep tissue or 
organ
129 135–997 MBS #30075, AR- 
DRG
Serum lactate dehydrogenase 
(LDH)
8 MBS # 66 500
Cost of treatment: 12- month 
cost—stage III unresectable/IV
115 072 1 05 208–1 25 573 29
Cost of treatment: 36- month 
cost—stage III unresectable/IV
187 599 1 75 520–2 00 130 29
AUD, Australian dollar; FNAB, fine needle aspiration biopsy.
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Analysis
The model will estimate the mean cost for each 
follow- up strategy and patients entering the model 
will be aged 18 years or older. The results of the cost- 
effectiveness analysis will be presented in incremental 
cost- effectiveness ratios (ICERs). The economic 
outcomes will be the cost per new distant melanoma 
recurrence appropriately detected and treated and 
cost per diagnostic error avoided, for the three strate-
gies when compared with no imaging. A deterministic 
analysis will be carried out for the base- case results for 
the different outcome measures.
Sensitivity analysis
A number of sensitivity analyses will be carried out as 
summarised below:
1. Deterministic sensitivity analyses will be undertaken to 
explore the effect of differences in test performance 
and costs of surveillance imaging in terms of the ICERs. 
A range of sensitivity and specificity values as well as 
costs will be sourced from the published literature.
2. A deterministic sensitivity analysis will be carried out 
on the extreme values for the range of prevalence of 
systemic recurrence found in the published trials and 
registry studies.
3. Probabilistic sensitivity analysis will be undertaken to 
determine the uncertainty of the model input param-
eters of sensitivity and specificity, prevalence and treat-
ment costs. Each model parameter will be assigned a 
distribution reflecting the amount and pattern of its 
variation, and cost- effectiveness results will be calcu-
lated by simultaneously selecting random values from 
each distribution. The process will be repeated 10 000 
times in a Monte Carlo simulation of the model to give 
an indication of how variation in the model parame-
ters leads to variation in the ICERs for a given imaging 
strategy. We will place a normal distribution for the 
data on test accuracy. Treatment costs point estimates 
will be derived from the literature.29 For costs we will 
place a Gamma distributionand a beta distribution for 
sensitivity, specificity and prevalence.
Reporting of the study design, methods and results will 
follow the Consolidated Health Economic Evaluation 
Reporting Standards.31
Ethics and dissemination
This study was approved by the Institutional Review 
Board’s ethics committee (MIA2016/182), the Australian 
Institute of Health and Welfare (EO2019-1-454) and the 
Royal Prince Alfred Hospital Ethics Committee X18-0144, 
LNR/18/RPAH/206.
The results of this study will inform the Cancer Council 
Australia’s melanoma guidelines Wiki.3 Additionally, the 
results of this study will be published in high- impact peer- 
reviewed medical and economic journals. A lay summary 
written in collaboration with consumers from Melanoma 
Patients Australia will be disseminated through social 
media channels.
DISCUSSION
After treatment of stage III melanoma, patients have 
regular follow- up with their treating doctors. Imaging 
techniques such as CT, PET or PET/CT for detec-
tion of distant disease are used alongside these visits. 
Routine surveillance aims to support and reassure 
patients and to detect systemic recurrence early so 
that appropriate treatment can be given in an optimal 
time frame. Furthermore, with new effective thera-
pies for stage IV disease, robust evidence regarding 
the most cost- effective approach for follow- up of stage 
III melanoma patients is needed. There is a lack of 
consensus and evidence- based guidelines regarding 
the optimal imaging modalities or the frequency of 
schedules to best identify asymptomatic systemic 
melanoma recurrences.
This study will provide a framework for estimating the 
cost- effectiveness of four follow- up strategies in resected 
stage III melanoma over a 5- year time frame following 
curative- intent surgical treatment.
Strengths and limitations: this is one of the first studies 
to estimate the cost- effectiveness of three follow- up regi-
mens compared with no imaging follow- up in melanoma. 
Furthermore, the analysis will be based on test accuracy 
data from a large cohort study of over 1000 patients with 
stage III and value of Information analysis will estimate the 
expected value of conducting a prospective randomised 
controlled trial of imaging surveillance to reduce deci-
sion uncertainty. Finally, the model structure accounts 
for clinical and policy- relevant outcomes including test 
accuracy.
There are some limitations to this study. First, the 
comparison of the three imaging schedules was not based 
on data from randomised trials and some selection bias 
might be introduced. The model structure was limited 
in the pathways for which data were unavailable, there-
fore, we had to make many assumptions. Second, the 
treatment cost and utility data will be obtained from 
the published literature. Furthermore, the comparison 
of the three imaging schedules was not based on data 
from randomised trials and some selection bias might be 
introduced.
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